Recombinant human insulin-like growth factor-I enhances whole body protein anabolism and significantly diminishes the protein catabolic effects of prednisone in humans without a diabetogenic effect.

1995 ◽  
Vol 80 (3) ◽  
pp. 869-874
Author(s):  
N Mauras ◽  
B Beaufrere
Keyword(s):  
Growth Factor ◽  
Human Insulin ◽  
Whole Body ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Body Protein ◽  
Factor I ◽  
Growth Factor I

Comparative Effects of Recombinant Human Insulin-Like Growth Factor I and Insulin on Whole-Body and Forearm Palmitate Metabolism in Man

1995 ◽  
Vol 88 (6) ◽  
pp. 681-686 ◽  
Author(s):  
Roland Laager ◽  
Ronald Ninnis ◽  
Ulrich Keller
Keyword(s):  
Growth Factor ◽  
Glucose Uptake ◽  
Human Insulin ◽  
Whole Body ◽  
Saline Control ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Factor I ◽  
Growth Factor I ◽  
High Doses

1. The effects of intravenous infusions of recombinant human insulin-like growth factor 1 and insulin on palmitate kinetics, lipolysis and on serum triacylglycerol were compared. Overnight-fasted normal subjects received high doses of insulin-like growth factor I (30 μgh−1 kg−1) and insulin (0.23 nmol h−1 kg−1; group 1), low doses of insulin-like growth factor I (5 μg h−1 kg−1) and insulin (0.04 nmol h−1 kg−1; group 2) or saline (control group). The doses of insulin-like growth factor I and insulin were equipotent with regard to increases in glucose uptake during 8 h euglycaemic clamping. 2. Whole-body palmitate flux (measured by continuous infusions of [2,2-D2]palmitate) was lowered dose-dependently by 68% ± 6% during insulin-like growth factor I and by 82% ± 2% during insulin after 8 h of infusions of high doses (insulin-like growth factor I versus insulin; not significant). Plasma palmitate, glycerol and triacylglycerol concentrations had decreased to a similar extent at the end of the infusions of both peptides at either dose. 3. The present results demonstrate that insulin-like growth factor I and insulin infused at doses which result in identical increases in glucose uptake during euglycaemic clamping are equipotent inhibitors of lipolysis.

Cost Effectiveness of Recombinant Human Insulin-Like Growth Factor I Therapy in Patients with ALS

1999 ◽  
Vol 15 (2) ◽  
pp. 179-195 ◽  
Author(s):  
Stacey J. Ackerman ◽  
Erin M. Sullivan ◽  
Kathleen M. Beusterien ◽  
Howard M. Natter ◽  
Deborah F. Gelinas ◽  
...  
Keyword(s):  
Cost Effectiveness ◽  
Growth Factor ◽  
Human Insulin ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Factor I ◽  
Growth Factor I

scholarly journals Novel markers to detect recombinant human insulin-like growth factor-I (rhIGF-I)/rhIGF binding protein-3 (rhIGFBP-3) misuse in athletes

2016 ◽  
Vol 9 (1) ◽  
pp. 30-37 ◽  
Author(s):  
Richard I. G. Holt ◽  
Nishan Guha ◽  
Walailuck Böhning ◽  
Christiaan Bartlett ◽  
David A. Cowan ◽  
...  
Keyword(s):  
Growth Factor ◽  
Human Insulin ◽  
Binding Protein ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Factor I ◽  
Growth Factor I

O-Mannosylation of recombinant human insulin-like growth factor I (IGF-I) produced inSaccharomyces cerevisiae

FEBS Letters ◽  
1989 ◽  
Vol 248 (1-2) ◽  
pp. 111-114 ◽  
Author(s):  
Karl Hård ◽  
Wilbert Bitter ◽  
Johannis P. Kamerling ◽  
Johannes F.G. Vliegenthart
Keyword(s):  
Growth Factor ◽  
Human Insulin ◽  
Insulin Like Growth Factor ◽  
Recombinant Human Insulin ◽  
Factor I ◽  
Igf I ◽  
Growth Factor I
Sign in / Sign up

Export Citation Format

Share Document